Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 22,009 matching trials from the local directory fallback.

Filters: Recruiting Clear all

Conditions: Inherited Bone Marrow Failure Syndromes, Severe Aplastic Anemia, Telomere Biology Disorders
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 99 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2041
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cigarette Smoking-Related Carcinoma
Interventions: Health Promotion and Education, Informational Intervention, Questionnaire Administration, Smoking Cessation Intervention; Other · Behavioral
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 224
States / cities: Kingman, Arizona • Fort Smith, Arkansas • St. Helena, California + 187 more

Conditions: Advanced Gastrointestinal Stromal Tumor, HIF-2α Mutated Cancers, Pancreatic Neuroendocrine Tumor, Pheochromocytoma/Paraganglioma, Von Hippel-Lindau Disease
Interventions: Belzutifan; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 12 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 14
States / cities: Los Angeles, California • Chicago, Illinois • Warrenville, Illinois + 10 more

Conditions: Carcinoma, Squamous Cell
Interventions: Cetuximab, JNJ-90301900 (NBTXR3), Radiation Therapy; Drug · Radiation
Lead sponsor: Johnson & Johnson Enterprise Innovation Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 26
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 23 more

Conditions: Atopic Dermatitis, Immune-mediated Diseases, Primary Immunodeficiency, Psoriasis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions: Cyclophosphamide, Doxorubicin, Duvelisib, Etoposide, Oral azacitidine, Prednisone, Vincristine; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 96
States / cities: Little Rock, Arkansas • Duarte, California • La Jolla, California + 74 more

Conditions: Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Interventions: Abemaciclib, Atezolizumab, Everolimus, Giredestrant, Inavolisib, Ipatasertib, PH FDC SC, Palbociclib, Ribociclib, Samuraciclib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 12
States / cities: Duarte, California • Irvine, California • San Francisco, California + 9 more

Conditions: Acute Myeloid Leukemia, Refractory, Acute Myeloid Leukemia, in Relapse, Refractory/Relapse Acute Myeloid Leukemia
Interventions: Ceramide NanoLiposome (Ceraxa); Drug
Lead sponsor: Keystone Nano, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Hemoglobinopathies
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2035
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Hematological Malignancies
Interventions: Talquetamab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 14
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 10 more

Conditions: Breast Cancer, Colorectal Cancer, Prostate Cancer, Stage I Breast Cancer, Stage I Colorectal Cancer, Stage I Prostate Cancer, Stage II Breast Cancer, Stage II Colorectal Cancer, Stage II Prostate Cancer, Stage III Breast Cancer, Stage III Colorectal Cancer, Stage III Prostate Cancer
Interventions: Exercise; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 9
States / cities: Durate, California • San Carlos, California • Basking Ridge, New Jersey + 6 more

Conditions: Post-Coronavirus Disease 19
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 1,590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Colitis, Ulcerative, Crohn Disease
Interventions: Other Biologic Therapies, Ustekinumab; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,536 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Liver Metastases
Interventions: PET/CT Scan, Tumor ablation (TA), [18-F]- FDG - PET; Diagnostic Test · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Cancer
Interventions: Bronchoscopy, Research Procedures; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: DM1, Myotonic Dystrophy 1
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 10
States / cities: La Jolla, California • Los Angeles, California • Denver, Colorado + 7 more

Conditions: Articular Cartilage Defect, Articular Cartilage Disorder of Knee, Chondral Defect, Osteochondritis Dissecans (OCD)
Interventions: MACI, microfracture; Biological · Procedure
Lead sponsor: Vericel Corporation; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 15
States / cities: Palo Alto, California • Sacramento, California • New Orleans, Louisiana + 10 more

Conditions: High Grade Glioma, Melanoma, Non Small Cell Lung Cancer, Rare Cancers, Solid Tumor
Interventions: dabrafenib, trametinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2032
U.S. locations: 4
States / cities: Scottsdale, Arizona • Bethesda, Maryland • Columbus, Ohio + 1 more

Conditions: Erdheim-Chester Disease
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: Biospecimen Collection, Computed Tomography with Contrast, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Osimertinib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 347
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Fort Smith, Arkansas + 238 more

Conditions: Colon Cancer, Gastric Cancer, Gastrointestinal Cancer, Pancreatic Cancer, Rectal Cancer
Interventions: Aldesleukin, Anti-KRAS G12V mTCR PBL, Cyclophosphamide, Fludarabine; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 72 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: B Acute Lymphoblastic Leukemia
Interventions: Allopurinol, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Inotuzumab Ozogamicin, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Pegylated L-Asparaginase, Rituximab, Thioguanine, Vincristine Sulfate; Drug · Procedure · Biological + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 39 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 455
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 279 more

Conditions: Cardiomyopathies, Channelopathy, Epilepsy, Seizures, Syncope
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 50 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Intracranial Meningioma, NF2 Gene Mutation, Recurrent Meningioma
Interventions: Abemaciclib, Capivasertib, FAK Inhibitor GSK2256098, Vismodegib; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 791
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 512 more

Search by objective public record fields.

Natural History of Acquired and Inherited Bone Marrow Failure Syndromes

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Metabolic Profiling of Immune Responses in Immune-mediated Diseases

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Discarded Bone Marrow for Hematology Research

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Researching the Effect of Exercise on Cancer

Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health

A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis

Tissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment

Longitudinal Evaluation of Microbial and Host Signatures During Immunotherapy for Lung Cancer

Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)

A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

Dabrafenib and/or Trametinib Rollover Study

Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Genetic Markers of Cardiovascular Disease in Epilepsy

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas